- Home
- BCLI vs CARM Comparison
BCLI vs CARM Comparison
Compare BCLI & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- CARM
- Stock Information
- Founded
- BCLI 2000
- CARM 2016
- Country
- BCLI United States
- CARM United States
- Employees
- BCLI N/A
- CARM N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- CARM Health Care
- Exchange
- BCLI Nasdaq
- CARM Nasdaq
- Market Cap
- BCLI 9.8M
- CARM 8.4M
- IPO Year
- BCLI N/A
- CARM N/A
- Fundamental
- Price
- BCLI $1.08
- CARM $0.42
- Analyst Decision
- BCLI Strong Buy
- CARM Hold
- Analyst Count
- BCLI 1
- CARM 5
- Target Price
- BCLI $30.00
- CARM $0.90
- AVG Volume (30 Days)
- BCLI 473.4K
- CARM 42.1M
- Earning Date
- BCLI 08-13-2025
- CARM 08-07-2025
- Dividend Yield
- BCLI N/A
- CARM N/A
- EPS Growth
- BCLI N/A
- CARM N/A
- EPS
- BCLI N/A
- CARM N/A
- Revenue
- BCLI N/A
- CARM $19,964,000.00
- Revenue This Year
- BCLI N/A
- CARM N/A
- Revenue Next Year
- BCLI N/A
- CARM N/A
- P/E Ratio
- BCLI N/A
- CARM N/A
- Revenue Growth
- BCLI N/A
- CARM 32.45
- 52 Week Low
- BCLI $0.72
- CARM $0.14
- 52 Week High
- BCLI $6.45
- CARM $1.90
- Technical
- Relative Strength Index (RSI)
- BCLI 43.20
- CARM 52.02
- Support Level
- BCLI $1.08
- CARM $0.41
- Resistance Level
- BCLI $1.32
- CARM $0.56
- Average True Range (ATR)
- BCLI 0.10
- CARM 0.13
- MACD
- BCLI -0.01
- CARM -0.01
- Stochastic Oscillator
- BCLI 4.00
- CARM 20.33
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.